Business ❯ Pharmaceutical Industry ❯ Drug Development

Market Competition

Novo Nordisk Eli Lilly Pricing Strategies Eli Lilly vs Novo Nordisk Sales Performance Stock Performance Obesity Drugs Insurance Coverage Insurance Policies Novo Nordisk's Market Position Regulatory Compliance Obesity Drug Market Cost Reduction Financial Deals Sales Projections Alternative Products Generic Drugs Consumer Health Weight Loss Products

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA Approves Palsonify, First Once-Daily Oral Treatment for Acromegaly

FDA Approves J&J’s Inlexzo Bladder Drug-Delivery Device for BCG‑Unresponsive NMIBC

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control